Bristol Myers Squibb Co
Oct 27, 2010 at 08:14 | Source: Reuters
Oct 18, 2010 at 19:14 | Source: CNBC-TV18
Oct 09, 2010 at 11:13 | Source: Reuters
Sep 08, 2010 at 08:30 | Source: Reuters
Nov 30, 2009 at 10:04 | Source: Reuters
Interact & exchange stock tips & market info »
Related News »
Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved the company's biologics manufacturing facility in Devens, Massachusetts for commercial production of ORENCIA ® (abatacept). The Devens ...
May 14, 2012 at 23:55 | Source: 4-traders (press release)
- Results of head-to-head study comparing two biologic drugs on a background of methotrexate for the treatment of moderate to severe rheumatoid arthritis to be presented Bristol-Myers Squibb Company [http://www.bms.com] today announced that the company ...
May 14, 2012 at 12:49 | Source: PressePortal.de
Schiff Adalimumab on Denver, CO Background Methotrexate in RA ... [1] Abatacept is the first biologic discovered and developed in Bristol-Myers Squibb research centres and abatacept IV was first approved for adult RA in May 2007 by the European ...
May 14, 2012 at 11:52 | Source: Marketwatch
The Paragon Report examines investing opportunities in the Drug Manufacturers - Major Industry and provides equity research on Merck & Co., Inc. (MRK - News) and Bristol Myers Squibb Co. (BMY - News). Access to full reports can be found at ...
May 25, 2012 at 17:58 | Source: Yahoo Finance
Takeda Pharmaceutical Co. and Bristol-Myers Squibb Co. (BMY) indicated to Amylin they also would make bids, the people said. Amylin began looking for suitors with Credit Suisse Group AG and Goldman Sachs Group Inc. after rejecting a $3.5 billion ...
May 25, 2012 at 17:58 | Source: Bloomberg
Bristol-Myers Squibb Company (BMY) today announced that the company ... The full set of abstracts can be accessed on the EULAR website. Abatacept is a selective co-stimulation modulator of T-cell activation. It is designed to prevent full ...
May 14, 2012 at 11:59 | Source: Yahoo Finance
Pharmaceuticals giant Bristol Myers Squibb Co. (BMY) on Friday caught some bullish commentary from analysts at BMO Capital. The firm initiated coverage on BMY with an “Outperform” rating and $39 price target, which suggests a 19% upside to ...
May 18, 2012 at 13:06 | Source: dividend.com
Stocks recently featured in the blog include Dr. Reddy's Laboratories ( RDY), Bristol-Myers Squibb & Co. ( BMY), Teva Pharmaceutical Industries Ltd. ( TEVA), Biogen Idec ( BIIB) and Elan Corporation, plc ( ELN). Get the most recent insight from ...
May 21, 2012 at 14:28 | Source: NASDAQ
Eli Lilly & Co. (LLY) and AstraZeneca Plc (AZN) won’t have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co. (BMY)’s Plavix after the drug loses U.S. patent protection today. Lilly’s Effient ...
May 17, 2012 at 04:10 | Source: Bloomberg